FI78079C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara substituerade 6-(2-aminoetyl)-bensoxazolinoner. - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara substituerade 6-(2-aminoetyl)-bensoxazolinoner. Download PDFInfo
- Publication number
- FI78079C FI78079C FI834315A FI834315A FI78079C FI 78079 C FI78079 C FI 78079C FI 834315 A FI834315 A FI 834315A FI 834315 A FI834315 A FI 834315A FI 78079 C FI78079 C FI 78079C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- compound
- compounds
- substituted
- benzyl
- Prior art date
Links
- -1 2-AMINOETHYL Chemical class 0.000 title claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 150000002431 hydrogen Chemical class 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims description 6
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylene tetramine Natural products C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- VAFVKRFDPSNZIJ-UHFFFAOYSA-N 6-(2-aminoethyl)-3h-1,3-benzoxazol-2-one Chemical group NCCC1=CC=C2NC(=O)OC2=C1 VAFVKRFDPSNZIJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004312 hexamethylene tetramine Substances 0.000 claims description 3
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims description 3
- 150000001412 amines Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000007787 solid Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 206010019280 Heart failures Diseases 0.000 abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000147 hypnotic effect Effects 0.000 abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 5
- 125000000217 alkyl group Chemical group 0.000 abstract description 3
- 125000003545 alkoxy group Chemical group 0.000 abstract description 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 238000010992 reflux Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000005337 ground glass Substances 0.000 description 8
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229960001412 pentobarbital Drugs 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VBDJHJKINJBDRR-UHFFFAOYSA-N 6-(2-bromoethyl)-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=C(CCBr)C=C2OC(=O)N(C)C2=C1 VBDJHJKINJBDRR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000004622 sleep time Effects 0.000 description 3
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- 125000005999 2-bromoethyl group Chemical group 0.000 description 2
- CPLWKJWNQCWKQV-UHFFFAOYSA-N 6-(2-bromoethyl)-3h-1,3-benzoxazol-2-one Chemical compound BrCCC1=CC=C2NC(=O)OC2=C1 CPLWKJWNQCWKQV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960001089 dobutamine Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- LFRHMTZYADABJZ-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)butan-2-amine;hydron;chloride Chemical compound Cl.CCC(N)CC1=CC=C2OCOC2=C1 LFRHMTZYADABJZ-UHFFFAOYSA-N 0.000 description 1
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 1
- AVJKDKWRVSSJPK-UHFFFAOYSA-N 1-(4-fluorophenyl)piperazine Chemical compound C1=CC(F)=CC=C1N1CCNCC1 AVJKDKWRVSSJPK-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DXCAMAPYWULPRC-UHFFFAOYSA-N 3-methyl-6-[2-(methylamino)ethyl]-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.CNCCC1=CC=C2N(C)C(=O)OC2=C1 DXCAMAPYWULPRC-UHFFFAOYSA-N 0.000 description 1
- HPYGOBMQUPYIRZ-UHFFFAOYSA-N 3-methyl-6-[2-(propan-2-ylamino)ethyl]-1,3-benzoxazol-2-one hydrobromide Chemical compound Br.CC(C)NCCC1=CC=C2N(C)C(=O)OC2=C1 HPYGOBMQUPYIRZ-UHFFFAOYSA-N 0.000 description 1
- BVXKNHUVADXQML-UHFFFAOYSA-N 6-(2-aminoethyl)-3-methyl-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.C1=C(CCN)C=C2OC(=O)N(C)C2=C1 BVXKNHUVADXQML-UHFFFAOYSA-N 0.000 description 1
- LAUINISNXLVCFD-UHFFFAOYSA-N 6-(2-bromoacetyl)-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=C(C(=O)CBr)C=C2OC(=O)N(C)C2=C1 LAUINISNXLVCFD-UHFFFAOYSA-N 0.000 description 1
- NGXKHAFEGIGYRA-UHFFFAOYSA-N 6-[2-(dipropylamino)ethyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound CCCN(CCC)CCC1=CC=C2N(C)C(=O)OC2=C1 NGXKHAFEGIGYRA-UHFFFAOYSA-N 0.000 description 1
- KHUHQDZUENTTRU-UHFFFAOYSA-N 6-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound COC1=CC=CC=C1N1CCN(CCC=2C=C3OC(=O)N(C)C3=CC=2)CC1 KHUHQDZUENTTRU-UHFFFAOYSA-N 0.000 description 1
- WCMKDIGTDOUQKL-UHFFFAOYSA-N 6-[2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=C2OC(=O)N(C)C2=CC=C1CCN(CC1)CCN1C1=CC=C(F)C=C1 WCMKDIGTDOUQKL-UHFFFAOYSA-N 0.000 description 1
- HASUMOLBAHIZLK-UHFFFAOYSA-N 6-[2-[benzyl(methyl)amino]ethyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C=1C=C2N(C)C(=O)OC2=CC=1CCN(C)CC1=CC=CC=C1 HASUMOLBAHIZLK-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- KHUHVSQTZLBPHE-UHFFFAOYSA-N BrCCC=1C=C2C(=NNO2)C(C1)=O Chemical compound BrCCC=1C=C2C(=NNO2)C(C1)=O KHUHVSQTZLBPHE-UHFFFAOYSA-N 0.000 description 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000004969 haloethyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8219812A FR2536749A1 (fr) | 1982-11-25 | 1982-11-25 | (amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique |
| FR8219812 | 1982-11-25 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI834315A0 FI834315A0 (fi) | 1983-11-24 |
| FI834315L FI834315L (fi) | 1984-05-26 |
| FI78079B FI78079B (fi) | 1989-02-28 |
| FI78079C true FI78079C (fi) | 1989-06-12 |
Family
ID=9279533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI834315A FI78079C (fi) | 1982-11-25 | 1983-11-24 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara substituerade 6-(2-aminoetyl)-bensoxazolinoner. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4558060A (enExample) |
| EP (1) | EP0110781B1 (enExample) |
| JP (1) | JPS59112976A (enExample) |
| KR (1) | KR910000416B1 (enExample) |
| AT (1) | ATE26270T1 (enExample) |
| AU (1) | AU562113B2 (enExample) |
| CA (1) | CA1208220A (enExample) |
| DE (1) | DE3370624D1 (enExample) |
| DK (1) | DK539983A (enExample) |
| ES (1) | ES8501233A1 (enExample) |
| FI (1) | FI78079C (enExample) |
| FR (1) | FR2536749A1 (enExample) |
| GR (1) | GR81294B (enExample) |
| HU (1) | HU190635B (enExample) |
| IE (1) | IE56285B1 (enExample) |
| PT (1) | PT77735B (enExample) |
| ZA (1) | ZA838684B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554284A (en) * | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones |
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| FR2637286A1 (fr) * | 1988-10-04 | 1990-04-06 | Adir | Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2643634A1 (fr) * | 1989-02-28 | 1990-08-31 | Adir | Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| US5182278A (en) * | 1989-02-28 | 1993-01-26 | Adir Et Compagnie | Analgesic benzoxazolinones having at the 6-position a 1-hydroxy-3-morpholinopropyl side chain |
| US5268381A (en) * | 1990-09-26 | 1993-12-07 | Adir Et Compagnie | Aminoalkyl-benzothiazolinone and -benzoxazolinone compounds having a high 5-HT1A affinity |
| FR2667068B1 (fr) * | 1990-09-26 | 1994-09-09 | Adir | Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5147881A (en) * | 1990-11-14 | 1992-09-15 | Pfizer Inc | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents |
| FR2674524B1 (fr) * | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5338846A (en) * | 1992-08-26 | 1994-08-16 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| FR2717810B1 (fr) * | 1994-03-22 | 1996-04-26 | Adir | Nouvelles aminoalkyl benzoxazolinones et benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| CN1182103C (zh) * | 1997-08-07 | 2004-12-29 | 株式会社富吉摩托普拉泽兹 | 乙胺衍生物 |
| US7213005B2 (en) * | 1999-12-09 | 2007-05-01 | International Business Machines Corporation | Digital content distribution using web broadcasting services |
| US20040192669A1 (en) * | 2000-04-13 | 2004-09-30 | Rosenfeld Mark J. | Novel compounds for use in weight loss and appetite suppression in humans |
| US7794761B2 (en) * | 2000-04-13 | 2010-09-14 | Seroctin Research & Technology, Inc. | Methods for inducing anti-anxiety and calming effects in animals and humans |
| US7524877B2 (en) | 2003-11-20 | 2009-04-28 | Seroctin Research & Technology, Inc. | Compounds for use in weight loss and appetite suppression in humans |
| EP1687300A4 (en) * | 2003-11-28 | 2007-08-01 | Wockhardt Ltd | PROCESS FOR THE PREPARATION OF ZIPRASIDONE MONOHYDROCHLORIDE HYDRATE |
| KR100812310B1 (ko) * | 2005-12-27 | 2008-03-10 | 주식회사이에스이 | 위치제어용 얼라인 장치 |
| CA2968806A1 (en) | 2014-12-05 | 2016-06-09 | Semmelweis University | Use of arylalkylamine monoamine oxidase inhibitors in the treatment or prevention of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4034100A (en) * | 1976-02-13 | 1977-07-05 | Merck & Co., Inc. | Antihypertensive agents |
| FR2491066A1 (fr) * | 1980-09-29 | 1982-04-02 | Cerm Cent Europ Rech Mauvernay | Benzoxazolinones substituees en 6 par une chaine aminoalcool ou aminocetone, leur preparation et leur application en therapeutique |
| FR2491471A1 (fr) * | 1980-10-03 | 1982-04-09 | Cerm Cent Europ Rech Mauvernay | Benzoxazolinones substituees, leur preparation et leur application en therapeutique |
| JPS57123103A (en) * | 1981-01-26 | 1982-07-31 | Hokko Chem Ind Co Ltd | Agricultural and horticultural fungicide |
| JPS61231548A (ja) * | 1985-04-05 | 1986-10-15 | Konishiroku Photo Ind Co Ltd | 写真廃液の処理方法及び写真自動現像機 |
-
1982
- 1982-11-25 FR FR8219812A patent/FR2536749A1/fr active Granted
-
1983
- 1983-11-21 ZA ZA838684A patent/ZA838684B/xx unknown
- 1983-11-22 US US06/554,194 patent/US4558060A/en not_active Expired - Fee Related
- 1983-11-23 AU AU21612/83A patent/AU562113B2/en not_active Ceased
- 1983-11-24 JP JP58221350A patent/JPS59112976A/ja active Pending
- 1983-11-24 AT AT83402267T patent/ATE26270T1/de not_active IP Right Cessation
- 1983-11-24 EP EP83402267A patent/EP0110781B1/fr not_active Expired
- 1983-11-24 ES ES527521A patent/ES8501233A1/es not_active Expired
- 1983-11-24 FI FI834315A patent/FI78079C/fi not_active IP Right Cessation
- 1983-11-24 GR GR73064A patent/GR81294B/el unknown
- 1983-11-24 IE IE2756/83A patent/IE56285B1/en not_active IP Right Cessation
- 1983-11-24 DE DE8383402267T patent/DE3370624D1/de not_active Expired
- 1983-11-24 HU HU834038A patent/HU190635B/hu not_active IP Right Cessation
- 1983-11-24 CA CA000441918A patent/CA1208220A/en not_active Expired
- 1983-11-25 PT PT77735A patent/PT77735B/pt not_active IP Right Cessation
- 1983-11-25 KR KR1019830005578A patent/KR910000416B1/ko not_active Expired
- 1983-11-25 DK DK539983A patent/DK539983A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK539983A (da) | 1984-05-26 |
| EP0110781B1 (fr) | 1987-04-01 |
| US4558060A (en) | 1985-12-10 |
| EP0110781A1 (fr) | 1984-06-13 |
| FI834315L (fi) | 1984-05-26 |
| HU190635B (en) | 1986-09-29 |
| CA1208220A (en) | 1986-07-22 |
| IE832756L (en) | 1984-05-25 |
| ZA838684B (en) | 1984-07-25 |
| AU2161283A (en) | 1984-05-31 |
| KR840006633A (ko) | 1984-12-01 |
| AU562113B2 (en) | 1987-05-28 |
| FR2536749A1 (fr) | 1984-06-01 |
| FI834315A0 (fi) | 1983-11-24 |
| DE3370624D1 (en) | 1987-05-07 |
| FI78079B (fi) | 1989-02-28 |
| ES527521A0 (es) | 1984-12-01 |
| DK539983D0 (da) | 1983-11-25 |
| ES8501233A1 (es) | 1984-12-01 |
| PT77735A (fr) | 1983-12-01 |
| ATE26270T1 (de) | 1987-04-15 |
| IE56285B1 (en) | 1991-06-05 |
| KR910000416B1 (ko) | 1991-01-25 |
| PT77735B (fr) | 1986-03-27 |
| FR2536749B1 (enExample) | 1985-04-26 |
| JPS59112976A (ja) | 1984-06-29 |
| GR81294B (enExample) | 1984-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI78079C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara substituerade 6-(2-aminoetyl)-bensoxazolinoner. | |
| AU645504B2 (en) | Bicyclic pyrimidine derivative, method of producing the same, and pharmaceutical preparation containing the same as active ingredient | |
| US4382938A (en) | Imidazo[1,2-a] pyridine derivatives and their application as pharmaceuticals | |
| EP0516234B1 (en) | Phenoxyphenyl derivatives | |
| FI67543C (fi) | Foerfarande foer framstaellning av farmakologiskt aktiv 2-(2-(1,4-benzodioxanyl))-2-imidazolin | |
| US5164397A (en) | 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their application in urinary therapeutics | |
| FI80268C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 1-pyrimidinyloxi-3-heteroarylalkylamino-2- propanolderivat. | |
| WO2003024937A1 (en) | Benzimidazolylalkoxyaryl alkanoic acid derivatives and their use as antihyperglycemics | |
| RU2695383C2 (ru) | Производные бендамустина, родственные соединения и их медицинское применение для лечения рака | |
| US5084456A (en) | Oxazolopyridine compounds | |
| EP1432709A1 (en) | 1-glyoxlylamide indolizines for treating cancer | |
| JPH02268172A (ja) | 新規なベンズオキサゾリノン誘導体 | |
| FR2663929A1 (fr) | Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| EA001780B1 (ru) | Производные пиридилкарбамоилиндолинов в качестве антагонистов 5-нт-рецепторов | |
| US5420130A (en) | 2-aminopyrazine-5-carboxamide derivatives, their preparation and their application in therapeutics | |
| WO2003011835A1 (en) | Benzimidazolylalkyl-aryl(alkan) oic acid derivatives and their use as antihyperglycaemics | |
| GB2071648A (en) | 3-Amino(1H,3H)quinazoline- 2,4-dione Derivatives, Process for Their Preparation and Their Therapeutic Applications | |
| HK1209725B (en) | Bendamustine derivatives and related compounds, and medical use thereof for cancer therapy | |
| KR20010052662A (ko) | 항당뇨병제로서의 α-(1-피페라지닐)아세트아미도아렌카르복실산 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: RIOM LABORATOIRES - C.E.R.M. |